The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Early & Long-Term Remission of Spondyloarthritis

Early & Long-Term Remission of Spondyloarthritis

July 16, 2021 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Strategy #1: His first approach centers on correctly using older drugs, including appropriately dosed non-steroidal anti-inflammatory drugs (NSAIDs), for SpA. In a study by van der Heijde et al., 387 patients with ankylosing spondylitis were randomized to receive one of two doses of etoricoxib (a cyclooxygenase 2 selective inhibitor) vs. 1,000 mg of naproxen daily vs. placebo. Over the initial six weeks of study, researchers found the patients receiving either etoricoxib or naproxen achieved statistically significant improvements in all co-primary end points: patient assessment of spine pain, patient global assessment of disease activity and the Bath Ankylosing Spondylitis Functional Index.2

You Might Also Like
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
Explore This Issue
August 2021
Also By This Author
  • Dendritic Cells as Therapeutics: The New Frontier

Dr. Van den Bosch also presented data indicating rates of partial remission in axial SpA, per the Assessment in SpondyloArthritis International Society (ASAS), with the use of naproxen are similar to the rates of minimal disease activity in PsA with the use of methotrexate. However, it should be noted that it’s challenging to compare different outcome measures in different diseases. Nevertheless, NSAIDs retain an important role in controlling disease activity for many patients, and rheumatologists would be wise to not neglect these therapies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Strategy #2: Dr. Van den Bosch’s next approach is based on the concept of using newer, more advanced medications to care for patients. Good data exists that minimal disease activity can be reached in such conditions as PsA with several modalities of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). Perhaps more challenging is knowing how to compare some of these medications in a head-to-head fashion.

Mease et al. compared the efficacy and safety of ixekizumab, an IL-17 inhibitor, with adalimumab, a tumor necrosis factor (TNF) α inhibitor, for the treatment of patients with PsA for whom conventional synthetic DMARD therapy proved inadequate. The authors found ixekizumab was superior to adalimumab in achieving simultaneous improvement of joint and skin disease, as measured by ACR50 criteria, and a 100% improvement from baseline in the Psoriasis Area and Severity Index (PASI-100).3 More head-to-head trials would be helpful in allowing clinicians to select one biologic or targeted synthetic DMARD over another in an effort to find the right therapy for each patient.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Strategy #3: This approach revolves around treat-to-target and tight disease control parameters. Dr. Van den Bosch pointed to the TICOPA trial, which sought to use an early intervention, treat-to-target approach for the care of patients with PsA. In this study, Coates et al. demonstrated tight control of PsA disease activity significantly improved joint and skin outcomes for patients with newly diagnosed disease. No unexpected severe adverse events were noted.4

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: AS Resource Center, EULAR, patient care, spondyloarthritisIssue: August 2021

You Might Also Like:
  • EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis
  • Treating Early-Stage Spondyloarthritis May Prevent Disease Progression, Say Researchers at the ACR/ARHP Winter Rheumatology Symposium
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)